MetaVia (NASDAQ:MTVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA) from a sell rating to a hold rating in a report published on Saturday morning.

Other research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. HC Wainwright reduced their price target on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Friday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $26.50.

MetaVia Price Performance

MTVA stock opened at $1.17 on Friday. MetaVia has a 1 year low of $1.17 and a 1 year high of $23.10. The company has a market cap of $2.57 million, a P/E ratio of -0.14 and a beta of 0.34. The stock’s fifty day moving average price is $1.77 and its 200-day moving average price is $6.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC grew its holdings in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.